首页> 外文期刊>International Urology and Nephrology >Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?
【24h】

Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?

机译:病理学家是否应该继续使用当前的pT2分类系统报告前列腺癌根治术标本?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objectives Pathologic staging tries to maintain symmetry with clinical staging, allowing a direct comparison of both. However, in contrast to clinical substaging of T2 prostate cancers, is controversial whether pathologic T2 substaging conveys prognostic information. The aim of our study is to analyze the clinicopathologic findings and the prognostic information comparing the clinical with the pathological T2 substaging of patients submitted to radical prostatectomy.
机译:目的病理分期试图与临床分期保持对称性,从而可以直接比较两者。然而,与T2前列腺癌的临床分型相反,病理性T2分型是否传达预后信息存在争议。我们研究的目的是分析临床和病理学的预后信息,比较接受前列腺癌根治术的患者的临床和病理T2分型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号